Skip to main content

Articles

FDA Approvals, In the News

Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma

ASH 2019 - Chronic Lymphocytic Leukemia

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory CLL: 42-Month Follow-Up of a Phase 2 Study

ASH 2019 - Chronic Lymphocytic Leukemia

Bendamustine-Rituximab versus Rituximab Monotherapy for Older Patients with Nodal or Splenic Marginal Zone Lymphoma

ASH 2019 - Chronic Lymphocytic Leukemia

Three-Year Update of the Phase 2 ABT-199 (Venetoclax) and Ibrutinib in Mantle-Cell Lymphoma (AIM) Study

ASH 2019 - Chronic Lymphocytic Leukemia

Lisocabtagene Maraleucel, a CD19-Directed CAR T-Cell Product, in High-Risk Patients with R/R CLL/SLL, Including Those Previously Treated with Ibrutinib

ASH 2019 - Chronic Lymphocytic Leukemia

Third Interim Analysis from the Phase 2 Vision HO141 Trial of Venetoclax + Ibrutinib for Patients with R/R CLL: 15-Month Safety, Response, and MRD Evaluation

ASH 2019 - Chronic Lymphocytic Leukemia

Phase 2 Results of the iR2 Regimen (Ibrutinib, Lenalidomide, and Rituximab) in Patients with Relapsed/Refractory Non-GCB DLBCL

ASH 2019 - Chronic Lymphocytic Leukemia

Bruton’s Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with CLL/SLL: Updated Results from a Phase 1/2 Trial

ASH 2019 - Chronic Lymphocytic Leukemia

Zanubrutinib in Patients with Treatment-Naïve CLL/SLL with Del(17p): Initial Results from Arm C of the Sequoia (BGB-3111-304) Trial

ASH 2019 - Chronic Lymphocytic Leukemia

Four-Year Analysis of MURANO Study, Evaluating Fixed-Duration Venetoclax + Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia

Page 42 of 244
Results 411 - 420 of 2434